Spots Global Cancer Trial Database for docetaxel
Every month we try and update this database with for docetaxel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | NCT00256282 | Metastatic Mela... | Vinorelbine Docetaxel Sargramostim | 18 Years - | University of California, Irvine | |
| Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial | NCT04872985 | Breast Cancer Hormone-recepto... | Pyrotinib Epirubicin Doxorubicin Hyd... Cyclophosphamid... Docetaxel Nab paclitaxel Placebo | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00402545 | Head and Neck N... | Cetuximab Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine | NCT00294385 | Breast Cancer | Docetaxel Gemcitabine, Do... Docetaxel | 18 Years - 75 Years | Central European Cooperative Oncology Group | |
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | NCT02485834 | Adenocarcinoma ... Gastric Adenoca... Gastric Cancer | FDG-PET surgery 5-FU capecitabine docetaxel Irinotecan 3D-CRT IMRT | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | NCT04947189 | Triple Negative... | Seviteronel-D (... Docetaxel | 18 Years - | St Vincent's Hospital, Sydney | |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | NCT03770299 | Non-Small Cell ... Non-Small-Cell ... Circulating Tum... | Nivolumab Vinorelbine Gemcitabine Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Observation | 18 Years - | Bristol-Myers Squibb | |
| A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | NCT00664170 | Advanced Cancer | ANX-514 docetaxel | 18 Years - | Mast Therapeutics, Inc. | |
| Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | NCT02685267 | Prostate Cancer | Docetaxel Enzalutamide Prednisone | 18 Years - | Prostate Cancer Clinical Trials Consortium | |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | NCT00569673 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim pegfilgrastim docetaxel trabectedin | 18 Years - 120 Years | GOG Foundation | |
| Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | NCT00214058 | Ovarian Carcino... Primary Periton... | Carboplatin Docetaxel | 18 Years - | University of Wisconsin, Madison | |
| Phase II Trial for Large ER-Negative Breast Cancers | NCT01869192 | Malignant Neopl... | Epirubicin Cyclophosphamid... Docetaxel Capecitabine Radiation Thera... | 18 Years - | University of Colorado, Denver | |
| Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer | NCT00212095 | Metastatic Brea... | docetaxel and k... | 18 Years - | National University Hospital, Singapore | |
| Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | NCT00321646 | Prostate Cancer Adenocarcinoma ... | Bevacizumab Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer | NCT06319313 | Squamous Cell N... | JMT101 docetaxel HB1801 | 18 Years - 75 Years | Shanghai JMT-Bio Inc. | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | NCT04882241 | Gastric Cancer Gastroesophagea... | Pembrolizumab Placebo Cisplatin Capecitabine 5-fluorouracil Docetaxel Oxaliplatin Leucovorin | 18 Years - | Merck Sharp & Dohme LLC | |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | NCT00313781 | Prostatic Neopl... | CP-751,871 docetaxel prednisone docetaxel prednisone | 18 Years - | Pfizer | |
| Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors | NCT00004923 | Unspecified Adu... | docetaxel irinotecan hydr... | 18 Years - | Yale University | |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | NCT01814150 | Metastatic Lung... Metastatic Brea... Metastatic Gast... Metastatic Pros... Metastatic Blad... | 18 Years - | Meir Medical Center | ||
| Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes | NCT06439225 | Metastatic Cast... Metastatic Pros... | Docetaxel Carboplatin | 18 Years - | Canadian Cancer Trials Group | |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00006104 | Breast Cancer | trastuzumab docetaxel | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | NCT06120075 | Advanced Cancer | AB801 Zimberelimab Docetaxel | 18 Years - | Arcus Biosciences, Inc. | |
| Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | NCT00714246 | Non Small Cell ... | Bortezomib Carboplatin Docetaxel | 18 Years - 90 Years | Milton S. Hershey Medical Center | |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | NCT00798252 | Advanced Cancer | Capecitabine Doxorubicin Ixabepilone Docetaxel Paclitaxel Brivanib alanin... | 18 Years - 75 Years | Bristol-Myers Squibb | |
| Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer | NCT01530295 | Prostate Cancer | DOCETAXEL | - | Asan Medical Center | |
| A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | NCT00664170 | Advanced Cancer | ANX-514 docetaxel | 18 Years - | Mast Therapeutics, Inc. | |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer | NCT03230734 | Metastatic Cast... | Radium-223 Docetaxel | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil | NCT00400205 | Squamous Cell C... Oral Cancer | Docetaxel Cisplatin 5-fluorouracil | 18 Years - | Emory University | |
| Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer | NCT00494338 | Metastatic Pros... | Docetaxel | 18 Years - | Sanofi | |
| A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | NCT00957125 | Breast Cancer | Epirubicin Docetaxel Bevacizumab | 18 Years - | Karolinska University Hospital | |
| Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma | NCT02088515 | Squamous Cell C... | Nedaplatin Cisplatin Docetaxel | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC | NCT00378404 | Non-Small Cell ... | Docetaxel Radiation | 18 Years - | University of Kentucky | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC | NCT03358875 | Non-small Cell ... | Tislelizumab Docetaxel | 18 Years - | BeiGene | |
| A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | NCT00545688 | Breast Cancer | Herceptin Docetaxel Pertuzumab | 18 Years - | Hoffmann-La Roche | |
| Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma | NCT03837977 | Oncology Neuroendocrine ... | Liposomal Irino... Fluorouracil Folinic Acid Docetaxel | 18 Years - | The Christie NHS Foundation Trust | |
| Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC) | NCT00995761 | Non-small Cell ... | Docetaxel and C... | 18 Years - 75 Years | Gyeongsang National University Hospital | |
| A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma | NCT03071042 | Metastatic Gast... | Apatinib Docetaxel | 18 Years - | Sir Run Run Shaw Hospital | |
| Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | NCT00183937 | Prostate Cancer | PS 341 Docetaxel | 18 Years - | University of Southern California | |
| Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer | NCT00003066 | Breast Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | NCT00093795 | Breast Cancer | Cyclophosphamid... Docetaxel Gemcitabine Paclitaxel Doxorubicin | 18 Years - | NSABP Foundation Inc | |
| MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors | NCT00004886 | Unspecified Adu... | docetaxel dofequidar fuma... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | NCT03137771 | Recurrent Non-S... Stage IV Non-Sm... | 3-Dimensional C... Docetaxel Gemcitabine Intensity-Modul... Pemetrexed Diso... Stereotactic Bo... Erlotinib Hydro... Pembrolizumab | 18 Years - | NRG Oncology | |
| Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | NCT02402712 | Breast Cancer | Docetaxel pertuzumab [Per... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | NCT01882985 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Docetaxel Lycopene | 21 Years - | University of California, Irvine | |
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | NCT05381038 | Solid Tumor Gastrointestina... Breast Cancer | QPOP CURATE.AI Azacitidine + d... Azacitidine + p... Azacitidine + i... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer | NCT00039520 | Breast Cancer | docetaxel sulindac | 18 Years - | Fox Chase Cancer Center | |
| Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC | NCT00280735 | Lung Cancer | carboplatin docetaxel | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | NCT01822613 | Esophageal Squa... | LJM716 BYL719 Paclitaxel Docetaxel Irinotecan | 18 Years - | Novartis | |
| Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00103389 | Lung Cancer | PI-88 docetaxel | 18 Years - 120 Years | Cellxpert Biotechnology Corp. | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| Taxotere New Indication - Gastric Cancer Treatment Registration Trial | NCT00811447 | Stomach Neoplas... | 5-fluorouracil Cisplatin Docetaxel | 18 Years - 70 Years | Sanofi | |
| A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. | NCT00471159 | Breast Neoplasm... | docetaxel PF-3512676 | 18 Years - | Pfizer | |
| Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | NCT03158129 | Stage I Lung No... Stage IA Lung N... Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Carboplatin Cisplatin Docetaxel Ipilimumab Nivolumab Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | NCT00288444 | Lung Cancer Soft Tissue Sar... Colorectal Carc... Breast Cancer Prostate Cancer | Lonafarnib Docetaxel | - | Emory University | |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | NCT00781612 | Neoplasm Metast... | Docetaxel Paclitaxel Pertuzumab Trastuzumab Trastuzumab Emt... Atezolizumab | 18 Years - | Genentech, Inc. | |
| Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | NCT04361708 | Pancreatic Aden... Gastroesophagea... Adenocarcinoma | Oxaliplatin Docetaxel Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | University of Chicago | |
| AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | NCT00372736 | Unspecified Adu... | AEG35156 docetaxel protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | NCT00003037 | Lung Cancer | cisplatin docetaxel gemcitabine hyd... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | NCT01652469 | Carcinoma, Non-... | Erlotinib Docetaxel | 18 Years - | ETOP IBCSG Partners Foundation | |
| Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer | NCT00002866 | Breast Cancer Neutropenia | filgrastim docetaxel epirubicin hydr... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer | NCT00040807 | Head and Neck C... | docetaxel irinotecan hydr... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | NCT01673867 | Non-Squamous Ce... | Nivolumab Docetaxel | 18 Years - | Bristol-Myers Squibb | |
| Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | NCT01862328 | Solid Tumors | MLN4924 Paclitaxel Gemcitabine Docetaxel Carboplatin | 18 Years - | Takeda | |
| Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer. | NCT00209729 | Gastric Cancer | Taxotere TS-1 | 76 Years - 80 Years | Hokkaido Gastrointestinal Cancer Study Group | |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy | NCT02753140 | Carcinoma, Squa... | Cetuximab radiation Docetaxel Cisplatin | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel | NCT00082134 | Hormone-refract... | ILX651 | 19 Years - | Sanofi | |
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | NCT01824901 | Recurrent Non-s... Squamous Cell L... | docetaxel AZD4547 | 25 Years - | Eastern Cooperative Oncology Group | |
| Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00006104 | Breast Cancer | trastuzumab docetaxel | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| German Preoperative Adriamycin Docetaxel Study | NCT00543829 | Breast Neoplasm... | doxorubicin, do... doxorubicin, do... | 18 Years - 70 Years | German Breast Group | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
